A5050543155- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Organ Transplantation Techniques and Outcomes
- Renal Transplantation Outcomes and Treatments
- Hepatitis B Virus Studies
- Gallbladder and Bile Duct Disorders
- Gastrointestinal disorders and treatments
- Liver Diseases and Immunity
- Tracheal and airway disorders
- Esophageal and GI Pathology
- Gastric Cancer Management and Outcomes
- Transplantation: Methods and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Neurological Complications and Syndromes
- Lung Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cytomegalovirus and herpesvirus research
- Esophageal Cancer Research and Treatment
- Hepatitis Viruses Studies and Epidemiology
Jacksonville College
2013-2024
Mayo Clinic in Florida
2015-2024
WinnMed
2014-2024
Nemours Children's Clinic
2022
Medical University of Vienna
2020
Ospedale regionale di Lugano
2020
Mayo Clinic
2007-2015
Mayo Clinic in Arizona
2010
Weatherford College
2006
Tricoci University of Beauty Culture
2005
There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, nucleotide polymerase sofosbuvir, ribavirin in infected HCV genotypes 1 or 4. Cohort A enrolled cirrhosis moderate severe hepatic impairment had not undergone transplantation. B transplantation: those without cirrhosis; mild, moderate, impairment; fibrosing cholestatic...
Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along minimal adverse events non–liver transplant (LT) patients hepatitis C virus (HCV) genotype 1 infection. This is the first multicenter report on efficacy, safety, tolerability of this LT recipients. A total 123 (76% male, 74% white, 60% 1a, 30% METAVIR F3‐F4, 4% decompensation, 11% cholestatic...
The use of donation after cardiac death (DCD) liver grafts is controversial because the overall increased rates graft loss and morbidity, which are mostly related to consequences ischemic cholangiopathy (IC). In this study, we sought determine factors leading development IC compare patient survival for recipients DCD brain (DBD) in a large series at single transplant center. Two hundred transplants with donors were performed between 1998 2010 Mayo Clinic Florida. Logistic regression models...
The safety, efficacy, and effect on immunosuppression levels of telaprevir (TVR) or boceprevir (BOC) in combination with peginterferon (PEG-IFN) ribavirin (RBV) recipients liver transplantation (LT) hepatitis C virus (HCV) genotype 1 have not been defined. We report our 3 centers' preliminary experiences administering triple antiviral treatment protocols containing PEG-IFN, RBV, TVR BOC. Patients biopsy-proven HCV recurrence (METAVIR grade ≥ and/or stage 2) received PEG-IFN/RBV for 12 weeks...
Hepatic artery thrombosis (HAT) and other vascular complications are significant causes of morbidity after liver transplantation. Although cigarette smoking increases the risk renal transplantation, its impact transplantation remains unknown. Between May 1995 April 2001, 288 transplantations were performed in 263 patients. Vascular developed 39 patients (13.5%) (arterial complications, 28 [9.7%]; venous 11 [3.8%]). Patient demographics, comorbid illnesses, factors analyzed using Mann-Whitney...
Objective: Hyperechogenic pancreas (HP) suggestive of fatty replacement is a common finding during endoscopic ultrasound (EUS). Recent data have implicated pancreatic steatosis as risk factor for pancreatitis and malignancy. Hepatic has been linked to obesity, increased age, hypertriglyceridemia, hyperglycemia, hyperinsulinemia. The objective this study was evaluate the effect body mass index (BMI), hepatic steatosis, other metabolic factors on HP seen EUS. Methods: Patients with were...
Long-term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients chronic HBV infection is inconvenient and costly. This randomized, prospective phase 2 study compared emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) HBIG withdrawal to FTC/TDF plus OLT. Forty a median time since 3.4 years (interquartile range = 1.9-5.6 years) received 24 weeks open-label before randomization. Patients who...
The diagnosis of chronic pancreatitis (CP) remains challenging. Endoscopic ultrasound (EUS) and magnetic resonance cholangiopancreatography (MRCP) have been proposed as highly accurate diagnostic modalities. Although endoscopic retrograde (ERCP) has previously used a gold standard, it is associated with small but significant risk. We aim to compare the accuracy EUS MRCP composite standard using ERCP, surgical pathology, and/or long-term clinical follow-up.Ninety-nine patients signs symptoms...
Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along minimal adverse events (AEs) patients genotype 1 (HCV GT1). The aim of this study was report on the response, safety, tolerability SOF SMV RBV compensated decompensated cirrhosis HCV GT1 Patients treated standardized clinical protocol utilizing SMV+SOF at three...
In the era of effective antiviral chemoprophylaxis, cytomegalovirus (CMV) disease has been inconsistently associated with increased mortality in liver transplant (LT) recipients. A retrospective study evaluating association CMV infection and occurring within 1 year endpoints death or combined endpoint graft loss was undertaken a cohort 227 donor seropositive, recipient seronegative first LT Associations were evaluated using Cox proportional hazards regression models. occurred 91 (40%) 43...
Although recurrent hepatitis C virus (HCV) after liver transplantation (LT) is universal, a minority of patients will develop cirrhosis within 5 years surgery, which places them at risk for allograft failure. This retrospective study investigated whether 2 serum fibrosis markers, hyaluronic acid (HA) and YKL-40, could be used to predict rapid progression (RFP) post-LT. These markers were compared with conventional laboratory tests, histological assessment, hepatic stellate cell activity...
Cytomegalovirus (CMV) has been inconsistently associated with recurrent hepatitis C virus (HCV) after liver transplant (LT).A retrospective study of 347, donor or recipient CMV seropositive, first LT recipients transplanted for HCV was performed to evaluate the associations infection and disease occurring within 1-year primary endpoints allograft inflammation grade ≥2 fibrosis stage ≥2. Associations were evaluated using multivariable Cox regression models.CMV occurred in 111 (32%) 24 (7%)...
Hepatitis C virus (HCV) infection is the most common indication for orthotopic liver transplantation in United States. Although studies have addressed use of expanded criteria donor organs HCV(+) patients, to date grafts from donation after cardiac death (DCD) donors patients has been by only a limited number studies. This retrospective analysis was undertaken study outcomes DCD used recipients. Seventy-seven who received were compared 77 matched brain (DBD) and unmatched non-HCV grafts....